Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients
Zili Hu,1,2,* Xuqi Sun,3,* Jie Mei,1,2,* Zhiwen Hu,1,2 Ziliang Yang,1,2 Jingyu Hou,1,2 Yizhen Fu,1,2 Xiaohui Wang,4 Minshan Chen1,2 1Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2Collaborative Innovation Cen...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-04-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/antiviral-treatments-eliminate-the-adverse-impacts-of-high-baseline-hb-peer-reviewed-fulltext-article-JHC |
| _version_ | 1818276236329222144 |
|---|---|
| author | Hu Z Sun X Mei J Hu Z Yang Z Hou J Fu Y Wang X Chen M |
| author_facet | Hu Z Sun X Mei J Hu Z Yang Z Hou J Fu Y Wang X Chen M |
| author_sort | Hu Z |
| collection | DOAJ |
| description | Zili Hu,1,2,* Xuqi Sun,3,* Jie Mei,1,2,* Zhiwen Hu,1,2 Ziliang Yang,1,2 Jingyu Hou,1,2 Yizhen Fu,1,2 Xiaohui Wang,4 Minshan Chen1,2 1Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 3Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 4Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, 410005, People’s Republic of China*These authors contributed equally to this workCorrespondence: Minshan Chen, Department of Liver Surgery, Sun Yat-sen University Cancer Center, Dongfeng Road East 651, Guangzhou, Guangdong, 510060, People’s Republic of China, Tel +86-20-87343117, Email chenmsh@sysucc.org.cn Xiaohui Wang, Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University), Jiefang Road West 61, Changsha, Hunan, 410005, People’s Republic of China, Tel +86-073183928052, Email xiaohuiwang21@163.comBackground: In consideration of no standard exclusion criteria for hepatitis B virus (HBV) loads in hepatocellular carcinoma (HCC)-related clinical trials, this study aimed to investigate the prevalence of HBV-related exclusion criteria among current clinical trials and evaluate whether antiviral treatments could eliminate the adverse effects from high HBV loads for HCC patients.Methods: This is a retrospective study including 772 HCC clinical trials on ClinicalTrials.gov and 1784 HCC patients receiving antiviral treatment. The Kaplan–Meier (K-M) method was used to compare the progression-free survival (PFS) and overall survival (OS) between different groups, and Cox regression analyses were performed to validate possible risk factors on PFS and overall survival OS.Results: Among 772 clinical trials, 58.3% did not adopt baseline HBV loads as exclusion criteria, 18.0% was 2000 IU/mL, and 10.5% was receiving antiviral therapy. We observed baseline HBV loads had no significant impact on PFS (p = 0.491, 0.155, 0.119, 0.788, 0.280, 0.683 respectively) and OS (p = 0.478, 0.741, 0.263, 0.039, 0.999, 0.581 respectively) in all patients or each treatment group including hepatectomy, radiofrequency ablation, interventional therapy, targeted drugs and anti-programmed cell death immunotherapy, except for the OS of interventional therapy group, where patients with high HBV loads had higher BCLC stage, serum AFP level and ALBI grade (p = 0.009, 0.015 and 0.003, respectively).Conclusion: Antiviral treatments could eliminate the adverse impacts of high HBV loads on the survival of HCC patients. Simplified eligibility criteria can be adopted for HCC patients with HBV infection where regular antiviral therapy should be enough.Keywords: hepatocellular carcinoma, hepatitis B virus loads, antiviral treatment, exclusion criteria, clinical trials |
| first_indexed | 2024-12-12T22:42:26Z |
| format | Article |
| id | doaj.art-7399ac4c34df4f198b6ee1089cb753e9 |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-12-12T22:42:26Z |
| publishDate | 2022-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-7399ac4c34df4f198b6ee1089cb753e92022-12-22T00:09:18ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692022-04-01Volume 931532574629Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC PatientsHu ZSun XMei JHu ZYang ZHou JFu YWang XChen MZili Hu,1,2,* Xuqi Sun,3,* Jie Mei,1,2,* Zhiwen Hu,1,2 Ziliang Yang,1,2 Jingyu Hou,1,2 Yizhen Fu,1,2 Xiaohui Wang,4 Minshan Chen1,2 1Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 3Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 4Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, 410005, People’s Republic of China*These authors contributed equally to this workCorrespondence: Minshan Chen, Department of Liver Surgery, Sun Yat-sen University Cancer Center, Dongfeng Road East 651, Guangzhou, Guangdong, 510060, People’s Republic of China, Tel +86-20-87343117, Email chenmsh@sysucc.org.cn Xiaohui Wang, Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University), Jiefang Road West 61, Changsha, Hunan, 410005, People’s Republic of China, Tel +86-073183928052, Email xiaohuiwang21@163.comBackground: In consideration of no standard exclusion criteria for hepatitis B virus (HBV) loads in hepatocellular carcinoma (HCC)-related clinical trials, this study aimed to investigate the prevalence of HBV-related exclusion criteria among current clinical trials and evaluate whether antiviral treatments could eliminate the adverse effects from high HBV loads for HCC patients.Methods: This is a retrospective study including 772 HCC clinical trials on ClinicalTrials.gov and 1784 HCC patients receiving antiviral treatment. The Kaplan–Meier (K-M) method was used to compare the progression-free survival (PFS) and overall survival (OS) between different groups, and Cox regression analyses were performed to validate possible risk factors on PFS and overall survival OS.Results: Among 772 clinical trials, 58.3% did not adopt baseline HBV loads as exclusion criteria, 18.0% was 2000 IU/mL, and 10.5% was receiving antiviral therapy. We observed baseline HBV loads had no significant impact on PFS (p = 0.491, 0.155, 0.119, 0.788, 0.280, 0.683 respectively) and OS (p = 0.478, 0.741, 0.263, 0.039, 0.999, 0.581 respectively) in all patients or each treatment group including hepatectomy, radiofrequency ablation, interventional therapy, targeted drugs and anti-programmed cell death immunotherapy, except for the OS of interventional therapy group, where patients with high HBV loads had higher BCLC stage, serum AFP level and ALBI grade (p = 0.009, 0.015 and 0.003, respectively).Conclusion: Antiviral treatments could eliminate the adverse impacts of high HBV loads on the survival of HCC patients. Simplified eligibility criteria can be adopted for HCC patients with HBV infection where regular antiviral therapy should be enough.Keywords: hepatocellular carcinoma, hepatitis B virus loads, antiviral treatment, exclusion criteria, clinical trialshttps://www.dovepress.com/antiviral-treatments-eliminate-the-adverse-impacts-of-high-baseline-hb-peer-reviewed-fulltext-article-JHChepatocellular carcinomahepatitis b virus loadsantiviral treatmentexclusion criteriaclinical trials |
| spellingShingle | Hu Z Sun X Mei J Hu Z Yang Z Hou J Fu Y Wang X Chen M Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients Journal of Hepatocellular Carcinoma hepatocellular carcinoma hepatitis b virus loads antiviral treatment exclusion criteria clinical trials |
| title | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
| title_full | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
| title_fullStr | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
| title_full_unstemmed | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
| title_short | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
| title_sort | antiviral treatments eliminate the adverse impacts of high baseline hbv loads on the survival of hbv related hcc patients |
| topic | hepatocellular carcinoma hepatitis b virus loads antiviral treatment exclusion criteria clinical trials |
| url | https://www.dovepress.com/antiviral-treatments-eliminate-the-adverse-impacts-of-high-baseline-hb-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT huz antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT sunx antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT meij antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT huz antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT yangz antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT houj antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT fuy antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT wangx antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT chenm antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients |